Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma
Open Access
- 1 February 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (3) , 1201
- https://doi.org/10.1182/blood-2002-09-2977
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.Journal of Clinical Immunology, 2002
- High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsBlood, 2001
- Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapyBlood, 2001
- Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term OutcomeJournal of Clinical Oncology, 2000
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalitiesBlood, 2000
- Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridizationBlood, 2000
- Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myelomaBone Marrow Transplantation, 1999